Financial results of fiscal 2023 Net sales decrease organically by 1.6% to € 21.0 billion EBITDA pre down organically by 9.0% to € ...
ICON plc (NASDAQ:ICLR), a global leader in healthcare intelligence and clinical research, announced its financial results for the fourth quarter and ...
Bio-Rad Laboratories Inc. reports a 6.7% decrease in fourth-quarter net sales compared to 2022, largely attributed to ongoing weakness in biopharma markets...
-IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services ...
Q2'24 net revenue of $1.03 billion decreased 10% as reported, or 11% in constant currency(1), compared to Q2'23. Q2'24 net revenue, excluding COVID...
Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") disclosed its financial performance for the fourth quarter and fiscal year 2023, includin...
Key Points: AstraZeneca announces robust financial performance for the full year and fourth quarter of 2023, marked by strong revenue growth and s...
Bristol Myers Squibb (NYSE: BMY) announced its financial results for the fourth quarter and full year of 2023, demonstrating robust performance, pipeline a...
“Thanks to the strong contributions from our team, we delivered differentiated performance in 2023 and enabled our customers’ success,” s...
Novartis, under the leadership of CEO Vas Narasimhan, has announced robust financial results for the full year of 2023. The company reported a 10% growth i...
Robust sales of CHF 6.7 billion, delivering 10.9%1 CER sales growth CORE EBITDA of CHF 2 billion, resulting in a margin of 29.8% Continued growth inves...
Fourth-quarter reported sales increased 1.5 percent; organic sales growth for the underlying base business increased 11.0 percent Full-year 2023 reporte...
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercial...
Medtronic plc announced financial results for its second quarter of fiscal year 2024 (FY24), which ended October 27, 2023. Key Highlights Revenue of $8...
© 2025 Biopharma Boardroom. All Rights Reserved.
